Workflow
舒泰神(300204.SZ)发布上半年业绩,归母净亏损2463.56万元
Staidson BioPharmStaidson BioPharm(SZ:300204) 智通财经网·2025-08-25 11:45

Core Insights - The company reported a significant decline in revenue and net loss for the first half of 2025, indicating challenging market conditions [1] Financial Performance - The company achieved an operating revenue of 126 million yuan, a year-on-year decrease of 31.14% [1] - The net loss attributable to shareholders was 24.6356 million yuan, with a net loss of 27.7167 million yuan after excluding non-recurring gains and losses [1] - Basic loss per share was 0.05 yuan [1] Segment Performance - Sales revenue from Su Tai Sheng reached 74.32 million yuan, accounting for 59.17% of total revenue, which is a decline of 5.71% compared to the same period last year [1] - Sales revenue from Shu Tai Qing was 41.69 million yuan, representing 33.19% of total revenue, with a significant decline of 57.88% year-on-year [1]